Rudy Ligtvoet

9PUBLICATIONS
33CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Probability theoryPredictive and prognostic markersStatistical mechanics, physical combinatorics and mathematical aspects of condensed matter
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Apr 14, 2026
Transition Into Clinical Routine and Survival Outcomes of BCL2- and BTK Inhibitors: An Analysis of Patient Data From the GCLLSG Registry.

Nadine Kutsch, Rudy Ligtvoet, Sandra Robrecht

|Sep 04, 2025
Acalabrutinib treatment for older (aged ≥80 years) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trial.

Florian Simon, Rudy Ligtvoet, Jan-Paul Bohn

|Jun 18, 2025
Inferences of associated latent variables by the observable test scores.

Rudy Ligtvoet

|Aug 30, 2024
End Point Surrogacy in First-Line Chronic Lymphocytic Leukemia.

Florian Simon, Rudy Ligtvoet, Sandra Robrecht

|Dec 09, 2023
Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial.

Othman Al-Sawaf, Rudy Ligtvoet, Sandra Robrecht

|Feb 06, 2022
Incomplete Tests of Conditional Association for the Assessment of Model Assumptions.

Rudy Ligtvoet

Pageof 2

Frequent Collaborators

5 joint publications

Michael J Hallek

4 joint publications

Sandra Robrecht

4 joint publications

Philipp Staber

3 joint publications

Othman Al-Sawaf